← Back to screener

Climb Bio, Inc. CLYM

Rank #2222 · Nasdaq · $0.6B market cap
Audited by PricewaterhouseCoopers LLP, no going-concern flag in the latest filing.
Score
28.6
P/E
-7.9
P/B
5.45
ROE
-68.7%
Op. Margin
–%
Debt Ratio
5%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Weak

P/E -7.9x, P/B 5.45x. Ranks in the top 77% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -68.7%. Ranks in the top 92% of the universe.

Safety ★★★★★
Excellent

Debt ratio 5%. Ranks in the top 8% of the universe. Under 100% is generally considered a safe level.

Growth –
No data

Not enough historical filings to compute year-over-year growth yet.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2021–$-0.0B$-0.0B$-0.0B–-55
2022–$-0.0B$-0.0B$-0.0B–-24
2023–$-0.0B$-0.0B$0.2B–4
2024–$-0.0B$-0.0B$0.1B–2
2025–$-0.1B$-0.1B$0.1B–5

← See the full screener